NM
ALLO icon

NWI Management’s Allogene Therapeutics ALLO Stock Holding History

NWI Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$208K Hold
100,000
– – 0.01% 55
2026
Q1 		$244K Hold
100,000
– – 0.01% 52
2025
Q4 		$137K Hold
100,000
– – 0.01% 57
2025
Q3 		$124K Hold
100,000
– – 0.01% 66
2025
Q2 		$113K Buy
+100,000
New +$133K 0.01% 56

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

NWI Management's ALLO Position: Q2 2026 in Review

NWI Management held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 100,000 shares worth $208K. The position accounts for 0.01% of the portfolio, ranked #55.

NWI Management first reported a position in ALLO in Q2 2025 and has held it in 5 quarters since. The position peaked at $244K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • NWI Management held 100,000 shares of Allogene Therapeutics worth $208K as of Q2 2026.
  • NWI Management left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up 0.01% of NWI Management's portfolio in Q2 2026, its #55 holding.
  • NWI Management first reported a position in Allogene Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • NWI Management's Allogene Therapeutics position peaked at $244K in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on NWI Management's 13F filing for Q2 2026, filed 14 Aug 2026.